Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the operating margin high or low?
The operating margin of -156.36% is 143% below its 5-year average of -64.39%, near the low end of its 5-year range (-222.08%–0.27%).
52.26% below its 12-month average of -102.69%.
Reported quarterly operating margin; no daily interpolation. Q2 FY2026 (2026-06-30): -59.51%.
OPERATING MARGIN
-156.36%
OPERATING MARGIN AVG TTM
-102.69%
OPERATING MARGIN AVG 3Y
-81.92%
OPERATING MARGIN AVG 5Y
-64.39%
OPERATING MARGIN AVG 10Y
-65.19%
OPERATING MARGIN AVG 15Y
N/A
OPERATING MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-52.26%
CURRENT VS 3Y AVG
-90.88%
CURRENT VS 5Y AVG
-142.82%
CURRENT VS 10Y AVG
-139.86%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 388 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Aquestive Therapeutics, Inc.
Market Cap
$573.38M
Operating Margin
-156.36%
TTM Avg
-102.69%
3Y Avg
-81.92%
5Y Avg
-64.39%
Market Cap
$569.56M
Operating Margin
46.95%
TTM Avg
-1.63%
3Y Avg
-11705.79%
5Y Avg
-12269.85%
Market Cap
$579.88M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$561.67M
Operating Margin
-29.35%
TTM Avg
-5.63%
3Y Avg
-52.07%
5Y Avg
-106.16%
Market Cap
$596.36M
Operating Margin
-975.91%
TTM Avg
-867.04%
3Y Avg
-586.91%
5Y Avg
-743.36%
Market Cap
$547.86M
Operating Margin
-1.90%
TTM Avg
-16.29%
3Y Avg
-781.66%
5Y Avg
-851.82%
Market Cap
$519.25M
Operating Margin
-230460.98%
TTM Avg
-373160.49%
3Y Avg
-159952.53%
5Y Avg
-107112.87%
Market Cap
$517.79M
Operating Margin
-1407.52%
TTM Avg
-703.76%
3Y Avg
-114341.22%
5Y Avg
-77223.74%
Market Cap
$517.73M
Operating Margin
0.00%
TTM Avg
-620906.82%
3Y Avg
-450471.78%
5Y Avg
-300340.85%
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | $573.38M | -156.36% | -102.69% | -81.92% | -64.39% |
| CorMedix Inc. (CRMD)vs › | $569.56M | 46.95% | -1.63% | -11705.79% | -12269.85% |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $579.88M | 0.00% | 0.00% | 0.00% | 0.00% |
| CytomX Therapeutics, Inc. (CTMX)vs › | $561.67M | -29.35% | -5.63% | -52.07% | -106.16% |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $596.36M | -975.91% | -867.04% | -586.91% | -743.36% |
| Delcath Systems, Inc. (DCTH)vs › | $547.86M | -1.90% | -16.29% | -781.66% | -851.82% |
| Altimmune, Inc. (ALT)vs › | $519.25M | -230460.98% | -373160.49% | -159952.53% | -107112.87% |
| Crescent Biopharma, Inc. (CBIO)vs › | $517.79M | -1407.52% | -703.76% | -114341.22% | -77223.74% |
| Allogene Therapeutics, Inc. (ALLO)vs › | $517.73M | 0.00% | -620906.82% | -450471.78% | -300340.85% |
| Climb Bio, Inc. (CLYM)vs › | $632.76M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
67.0%
Operating Margin
-156.4%
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | OPERATING MARGIN |
|---|---|
| 2026-06-30 | -59.51% |
| 2026-03-31 | -29.10% |
| 2025-12-31 | -221.58% |
| 2025-09-30 | -89.63% |
| 2025-06-30 | -113.65% |
| 2025-03-31 | -222.08% |
| 2024-12-31 | -114.43% |
| 2024-09-30 | -61.22% |
| 2024-06-30 | 0.27% |
| 2024-03-31 | -74.31% |
| 2023-12-31 | -29.62% |
| 2023-09-30 | -18.28% |
| 2023-06-30 | -31.79% |
| 2023-03-31 | -41.36% |
| 2022-12-31 | -100.29% |
| 2022-09-30 | -77.23% |
| 2022-06-30 | -96.21% |
| 2022-03-31 | -79.36% |
| 2021-12-31 | -105.33% |
| 2021-09-30 | -59.97% |
| 2021-06-30 | -42.47% |
| 2021-03-31 | -76.65% |
| 2020-12-31 | -218.86% |
| 2020-09-30 | -166.84% |
| 2020-06-30 | 1.82% |
| 2020-03-31 | -158.14% |
| 2019-12-31 | -60.32% |
| 2019-09-30 | -88.60% |
| 2019-06-30 | -167.92% |
| 2019-03-31 | -103.41% |
| 2018-12-31 | -73.40% |
| 2018-09-30 | -69.38% |
| 2018-06-30 | -234.68% |
| 2018-03-31 | 22.66% |
| 2017-12-31 | -59.50% |
| 2017-09-30 | 38.39% |
| 2017-06-30 | -36.43% |
| 2017-03-31 | 4.75% |
